Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation (NCT07211958)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Goodyear, Arizona
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (109 Sites)
Showing the first 25 of 109 sites.
- Clinical Trial Site — Goodyear, Arizona
- Clinical Trial Site — Duarte, California
- Clinical Trial Site — Shreveport, Louisiana
- Clinical Trial Site — South Brisbane, Queensland
- Clinical Trial Site — Melbourne, Victoria
- Clinical Trial Site — Nedlands, Western Australia
- Clinical Trial Site — Perth, Western Australia
- Clinical Trial Site — Gosford,
- Clinical Trial Site — Wollongong,
- Clinical Trial Site — Klagenfurt, Kaerten
- Clinical Trial Site — Sankt Pölten, Lower Austria
- Clinical Trial Site — Graz, Styria
- Clinical Trial Site — Leoben, Styria
- Clinical Trial Site — Linz,
- Clinical Trial Site — Ghent,
- Clinical Trial Site — Fortaleza, Paraná
- Clinical Trial Site — Barretos, São Paulo
- Clinical Trial Site — Jaú,
- Clinical Trial Site — Porto Alegre,
- Clinical Trial Site — Montreal,
- Clinical Trial Site — Toronto,
- Clinical Trial Site — Nice, Alpes-Maritimes
- Clinical Trial Site — Strasbourg, Bas-Rhin
- Clinical Trial Site — Angers, Loire-Atlantique
- Clinical Trial Site — Pessac, Pas-de-Calais
📞 Contact the Study Coordinator
Phone: (781) 419-1400
Email: clinicaltrials@syndax.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemias
Explore by condition: All Acute Myeloid Leukemias clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.